Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.

Abstract

BACKGROUND:

The adequacy of exposure of purine analogs as measured by 6-thioguanine nucleotides concentrations in the setting of combination therapy remains poorly understood. The aim of this study was to investigate the relationship between the mean corpuscular volume (MCV) value (as a surrogate marker of 6-thioguanine nucleotides concentration) and Crohn's disease outcomes in the setting of combination therapy with infliximab.

METHODS:

The SONIC trial was a randomized controlled trial comparing infliximab to azathioprine and to infliximab plus azathioprine in 508 Crohn's disease patients. An increase of at least 7 femtoliter (fL) of the MCV (ΔMCV) was used for statistical analysis.

RESULTS:

At week 26, the mean increase of MCV was similar among patients treated with azathioprine alone (mean of 7.9 fL) or in combination with infliximab (mean of 8.5 fL). In the azathioprine group, 63.6% of patients with ΔMCV >7 were in steroid-free clinical remission at week 26 as compared with 33.3% of patients without ΔMCV >7 (P = 0.0046). In the combination therapy group, ΔMCV above 7 was associated with mucosal healing (75.0% for ΔMCV >7 versus 47.1% for ΔMCV <7, P = 0.0172) but not with steroid-free clinical remission. Patients with a ΔMCV above 7 were more likely to have infliximab trough level above 3 μg/mL at week 30 (68.4% versus 38.8% for ΔMCV <7, P = 0.0032).

CONCLUSIONS:

These results suggest that ΔMCV above 7 (which is a surrogate for a higher 6-thioguanine nucleotides concentration) leads to improved Crohn's disease outcomes, even when combined with infliximab. It also suggests the possibility that a lower azathioprine exposure might be less effective in combination therapy.

• Authors: Guillaume Bouguen, Charles Sninsky, Kezhen L Tang, Jean-Frederic Colombel, Geert DʼHaens, Asher Kornbluth, Gerassimos J Mantzaris, Daniel Rachmilewitz, Walter Reinisch, Paul Rutgeerts, Mark Molenda, C Jannekevan der Woude, William J Sandborn
• Journal: Inflammatory bowel diseases (Inflamm Bowel Dis) Vol. 21 Issue 3 Pg. 606-14 (Mar 2015) ISSN: 1536-4844 [Electronic] England
• PMID: 25581826 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers
• Gastrointestinal Agents
• Immunosuppressive Agents
• Infliximab
• Azathioprine

Topics

• Adult
• Azathioprine (therapeutic use)
• Biomarkers (analysis)
• Crohn Disease (drug therapy, pathology)
• Double-Blind Method
• Drug Therapy, Combination
• Erythrocyte Indices (drug effects)
• Erythrocytes (drug effects, pathology)
• Female
• Gastrointestinal Agents (therapeutic use)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Infliximab (therapeutic use)
• Male
• Mucous Membrane (drug effects, pathology)
• Prognosis
• Wound Healing (drug effects)